774 results match your criteria: "Cancer Institute "Ion Chiricuta"[Affiliation]"
Eur J Nutr
September 2023
Department of Molecular Biology and Biotechnology, Faculty of Biology and Geology, "Babes-Bolyai" University, 5-7 Clinicilor Street, 400006, Cluj-Napoca, Romania.
Rom J Morphol Embryol
May 2023
Department of Radiotherapy, Prof. Dr. Ion Chiricuţă Oncology Institute, Cluj-Napoca, Romania;
Head and neck cancers include a wide variety of tumor sites that originate in the epithelium of the upper aerodigestive airways. The curative treatment of this group of pathologies most frequently involves multidisciplinary approach in which radiotherapy (RT) plays a central role. Treatment failures are mainly due to recurrences and local or regional evolution and rarely to distant metastases, which emphasizes the importance of ensuring local control.
View Article and Find Full Text PDFExpert Rev Anticancer Ther
June 2023
Department of Hematology/Oncology, Clinic for Internal Medicine IV-Hematology/Oncology, University Clinic, Martin Luther University Halle-Wittenberg Germany.
Introduction: Targeting HER2 has led to a revolution in therapy for cancers such as breast and gastric cancer, HER2 amplification is rarer (just 2-6%) in colorectal cancer (CRC) and efforts to target this receptor have lagged. Despite recent FDA approval for the first directed therapy combination for HER2 amplified metastatic CRC, the EMA has not yet authorized any such treatment and this represents a persistent unmet need in Europe and beyond. Here, we review data from trials targeting HER2 amplification, the latest target for CRC therapy.
View Article and Find Full Text PDFDiagnostics (Basel)
April 2023
"Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, 010336 Cluj-Napoca, Romania.
Gastric cancer is the fifth type of neoplasia most frequently diagnosed and the fourth cause of death among other cancers. Prevalence is around two times higher for males than females. Chitotriosidase and neopterin are two molecular biomarkers with potential diagnostic and prognostic use in malignant pathology.
View Article and Find Full Text PDFMolecules
March 2023
Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Two diphenyl formamidine ligands, four dirhodium(II,II) complexes, and three axially modified low-valent dirhodium(II,II) metallodendrimers were synthesized and evaluated as anticancer agents against the A2780, A2780, and OVCAR-3 human ovarian cancer cell lines. The dirhodium(II,II) complexes show moderate cytotoxic activity in the tested tumor cell lines, with acetate and methyl-substituted formamidinate compounds displaying increased cytotoxicity that is relative to cisplatin in the A2780 cisplatin resistant cell line. Additionally, methyl- and fluoro-substituted formamidinate complexes showed comparable and increased cytotoxic activity in the OVCAR-3 cell line when compared to cisplatin.
View Article and Find Full Text PDFMedicina (Kaunas)
March 2023
Department of Oncology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Ovarian cancer is the most lethal gynecologic malignancy. Platinum-based chemotherapy is the backbone of treatment for ovarian cancer, and although the majority of patients initially have a platinum-sensitive disease, through multiple recurrences, they will acquire resistance. Platinum-resistant recurrent ovarian cancer has a poor prognosis and few treatment options with limited efficacy.
View Article and Find Full Text PDFBreast
June 2023
Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal; Faculty of Medicine, University of Lisbon, Lisbon, Portugal. Electronic address:
Simple breast conservation surgery (sBCS) has technically advanced onto oncoplastic breast procedures (OBP) to avoid mastectomy and improve breast cancer patients' psychosocial well-being and cosmetic outcome. Although OBP are time-consuming and expensive, we are witnessing an increase in their use, even for cases that could be managed with sBCS. The choice between keeping it simple or opting for more complex oncoplastic procedures is difficult.
View Article and Find Full Text PDFInt J Mol Sci
February 2023
Department of Surgical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuta" Cluj-Napoca, 400015 Cluj-Napoca, Romania.
Exosomes are nanosized vesicles that have been found to be involved in many diseases. Exosomes can mediate communication between cells in a variety of ways. Certain types of mediators derived from cancer cells can play a crucial role in the development of this pathology, promoting tumor growth, invasion, metastasis, angiogenesis, and immunomodulation.
View Article and Find Full Text PDFCancers (Basel)
February 2023
Gynecologic Oncology Unit, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain.
Background: The aim of this study was to assess the impact of prognostic factors on the survival of patients diagnosed with uterine carcinosarcoma.
Methods: A sub-analysis of the SARCUT study, a multicentric retrospective European study, was carried out. We selected 283 cases of diagnosed uterine carcinosarcoma for the present study.
BioDrugs
May 2023
Medical Science Division, Celltrion, Inc., 23, Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea.
Background: The Phase 3 CT-P6 3.2 study demonstrated equivalent efficacy and comparable safety between CT-P6 and reference trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer after up to 3 years' follow-up.
Objective: To investigate long-term survival with CT-P6 and reference trastuzumab.
Cancer Res
June 2023
Research Center for Advanced Medicine - MedFUTURE, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
The ubiquitin-proteasome system (UPS) is responsible for up to 90% of intracellular protein degradation. Alterations in UPS are extensively involved in the development and advancement of malignant pathologies. Thus, the components of the UPS can become potential targets for cancer therapeutics.
View Article and Find Full Text PDFEur J Cancer
April 2023
Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Electronic address:
Background: In CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus chemotherapy (4 cycles) in patients with metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years).
Methods: In patients (N = 719) randomised 1:1 to nivolumab plus ipilimumab with chemotherapy or chemotherapy alone, disease-related symptom burden and health-related quality of life were assessed using the Lung Cancer Symptom Scale (LCSS) and 3-level EQ-5D (EQ-5D-3L).
Polymers (Basel)
February 2023
Department of Analytical Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
(1) Background: The current limitations of glioblastoma (GBM) chemotherapy were addressed by developing a molecularly imprinted polymer (MIP)-based drug reservoir designed for the localized and sustained release of ruxolitinib (RUX) within the tumor post-resection cavity, targeting residual infiltrative cancerous cells, with minimum toxic effects toward normal tissue. (2) Methods: MIP reservoirs were synthesized by precipitation polymerization using acrylamide, trifluoromethacrylic acid, methacrylic acid, and styrene as monomers. Drug release profiles were evaluated by real-time and accelerated release studies in phosphate-buffered solution as a release medium.
View Article and Find Full Text PDFFuture Oncol
March 2023
Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France.
What Is This Summary About?: In this article, we summarize results from the ongoing phase 3 CheckMate 816 clinical study that were published in in 2022. The goal of CheckMate 816 was to find out if , an immunotherapy that activates a person's immune system (the body's natural defense system) to fight cancer, works better than when given before surgery in people with non-small-cell lung cancer (NSCLC) that can be removed surgically (resectable NSCLC).
What Happened In The Study?: Adults who had not previously taken medications to treat NSCLC and whose cancer could be removed with surgery were included in CheckMate 816.
Front Oncol
January 2023
Leeds Cancer Center, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Introduction: Much drug development and published analysis for epithelial ovarian cancer (EOC) focuses on early-line treatment. Full sequences of treatment from diagnosis to death and the impact of later lines of therapy are rarely studied. We describe the establishment of an international network of cancer centers configured to compare real-world treatment pathways in UK, Portugal, Germany, South Korea, France and Romania (the Ovarian Real-World International Consortium; ORWIC).
View Article and Find Full Text PDFHealthcare (Basel)
January 2023
Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta.
Unlabelled: Eastern Europe continues to have the highest rates of cancer of the uterine cervix (CUC) and human papillomavirus (HPV) infection in Europe.
Aim: The aim of this study was to investigate CUC trends in Bulgaria in the context of a lack of a population-based screening program and a demographic crisis.
Methodology: This was a retrospective study of 7861 CUC patients who were registered in the Bulgarian National Cancer Registry (BNCR) between 2013 and 2020 and followed up with until March 2022.
Diagnostics (Basel)
January 2023
Radiology and Imaging Department, County Emergency Hospital, Clinicilor Street, Number 3-5, 400006 Cluj-Napoca, Romania.
The conventional magnetic resonance imaging (MRI) evaluation and staging of cervical cancer encounters several pitfalls, partially due to subjective evaluations of medical images. Fifty-six patients with histologically proven cervical malignancies (squamous cell carcinomas, = 42; adenocarcinomas, = 14) who underwent pre-treatment MRI examinations were retrospectively included. The lymph node status (non-metastatic lymph nodes, = 39; metastatic lymph nodes, = 17) was assessed using pathological and imaging findings.
View Article and Find Full Text PDFBlood Rev
May 2023
Centre for Haematology, Imperial College of Science, Technology and Medicine, London, UK; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting.
View Article and Find Full Text PDFJ Immunother Cancer
February 2023
Medical Oncology Department, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Comunidad de Madrid, Spain.
Background: CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (cohort A) and special populations (cohort A1: ECOG PS 2; or ECOG PS 0-1 with untreated brain metastases, renal impairment, hepatic impairment, or controlled HIV infection).
Methods: Cohorts A and A1 received nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks.
Cancers (Basel)
January 2023
Department of Surgical Oncology and Gynaecological Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Background: Frequently, patients treated for Ovarian Cancer (OC) undergo menopause with subsequent symptoms. This review scrutinised the impact of Hormone Replacement Therapy (HRT) on the Overall Survival (OS) and Progression-Free Survival (PFS) of patients diagnosed with OC. Methods: A systematic literature search was conducted in the most popular English databases.
View Article and Find Full Text PDFCurr Issues Mol Biol
January 2023
1st Department of Anesthesia and Intensive Care, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Background: Colorectal cancer is highly common and causes high mortality rates. Treatment for colorectal cancer is multidisciplinary, but in most cases the main option remains surgery. Intriguingly, in recent years, a number of studies have shown that a patient's postoperative outcome may be influenced by certain anesthetic drugs.
View Article and Find Full Text PDFMedicina (Kaunas)
December 2022
3rd Department of Surgery, "Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.
Background and Objectives: The aim was to evaluate the association of inflammatory biomarkers with resectability and overall survival in hilar cholangiocarcinoma. Materials and Methods: We conducted a retrospective cohort study over 72 consecutive surgical cases of Klatskin tumor over an 11-year period. The sample was divided into two groups: 42 surgical resection cases and 30 unresectable tumors.
View Article and Find Full Text PDFJ Clin Med
December 2022
Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.
Hematological malignancies are considered to be one of the most important causes of mortality and morbidity in the modern world [...
View Article and Find Full Text PDFDiagnostics (Basel)
December 2022
Radiotherapy Center Amethyst Cluj-Napoca, 407280 Cluj, Romania.
Radiotherapy (RT) plays a crucial role in all stages of lung cancer. Data on recent real-world RT patterns and main drivers of RT decisions in lung cancer in Romania is scarce; we aimed to address these knowledge gaps through this physician-led medical chart review in 16 RT centers across the country. Consecutive patients with lung cancer receiving RT as part of their disease management between May-October 2019 (pre-COVID-19 pandemic) were included.
View Article and Find Full Text PDFCurr Oncol
November 2022
"Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, Croitorilor Str., No. 19-21, 400162 Cluj-Napoca, Romania.
Our study aimed to evaluate the baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII) in relation to invasion, metastasis, and resectability for patients with gastric cancer, respectively, as predictors of death during hospitalization or surgical complications. A retrospective cohort study was conducted on 657 gastric cancer subjects. Inflammatory biomarkers were computed.
View Article and Find Full Text PDF